The Apis Team will be exhibiting and speaking in-person at the 12th Clinical Biomarker & CDx Summit Europe in London (UK).

Be sure not to miss Apis’ Dr Ian Kavanagh (Co-founder & COO) talking on ‘Development of a novel breast cancer subtyping and proliferation gene expression diagnostic test’ in the plenary session on Thursday 28th April @ 08.30 – 09.00 (UK).

Abstract

Apis is taking from discovery to CE-IVD a RT-qPCR nucleic acid-based test for the detection and relative gene expression quantification of human mRNA target genes from pre-operative CNB or resected FFPE breast tumour tissue from patients with invasive breast cancer.

The breast cancer subtyping performance of the test has been determined by concordance to that assigned by the current histopathology IHC reference methodology.

A novel ‘proliferative signature’ has been identified and included that allows for discrimination of Luminal A and Luminal B subtyping tumours over MKI67 alone.

In this talk we will describe the biomarker discovery approach undertaken and detail the development of the diagnostic test from design input to its final product manufacturing.

Interested in learning more? Use this link to contact us and schedule a meeting.